Kalaris Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No N-PORT holders.
No thesis.
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Samsara BioCapitalSamsara BioCapital | $52.4M | 71.44% | −0.52% | |
| 2 | RTW InvestmentsRTW | $5.3M | 7.21% | 0.00% | |
| 3 | Alyeska Investment GroupAlyeska Investment | $2.3M | 3.18% | 0.00% | |
| 4 | SirenSiren | $1.8M | 2.42% | 0.00% | |
| 5 | Vanguard Capital ManagementVanguardindex-like | $1.6M | 2.21% | +56.14% | |
| 6 | Ikarian CapitalIkarian Capital | $1.5M | 2.00% | 0.00% | |
| 7 | UBS GroupUBS | $1.1M | 1.45% | +4138.86% | |
| 8 | Renaissance TechnologiesRenaissance Technologies | $607,859 | 0.83% | +125.77% | |
| 9 | Marshall WaceMarshall Wace | $566,549 | 0.77% | +105.07% | |
| 10 | Geode Capital ManagementGeodeindex-like | $464,287 | 0.63% | +30.26% | |
| 11 | Woodline PartnersWoodline Partners | $407,000 | 0.55% | 0.00% | |
| 12 | ADAR1 Capital ManagementADAR1 | $407,000 | 0.55% | 0.00% | |
| 13 | WHI TRUSTWHI TRUST | $396,797 | 0.54% | 0.00% | |
| 14 | Raymond James FinancialRaymond James Financial | $395,457 | 0.54% | −18.27% | |
| 15 | Citadel AdvisorsCitadel | $389,792 | 0.53% | new | |
| 16 | Boothbay Fund ManagementBoothbay Fund | $375,502 | 0.51% | 0.00% | |
| 17 | Verdad AdvisersVerdad | $326,809 | 0.45% | new | |
| 18 | Morgan StanleyMorgan Stanley | $294,367 | 0.40% | +88.62% | |
| 19 | Vanguard Fiduciary TrustVanguard Fiduciary Trustindex-like | $269,349 | 0.37% | +80.24% | |
| 20 | BlackRockBlackRockindex-like | $221,580 | 0.30% | +51.05% | |
| 21 | Belpointe Asset ManagementBelpointe | $162,800 | 0.22% | 0.00% | |
| 22 | Fortis Capital AdvisorsFortis Capital | $162,800 | 0.22% | 0.00% | |
| 23 | Pale Fire CapitalPale Fire Capital | $161,278 | 0.22% | new | |
| 24 | Squarepoint OpsSquarepoint Ops | $157,814 | 0.22% | −2.51% | |
| 25 | Bridgeway Capital ManagementBridgeway | $132,275 | 0.18% | +44.44% |
55 managers report $73.4M of Kalaris Therapeutics on form 13F for the quarter ended Jun 30 '26. 3 of them hold 80% of it; Samsara BioCapital is largest at 71.44%.
Kalaris Therapeutics, Inc.
2.04
Expected move
No implied move.